{"filing":{"accession_number":"0001193125-26-342667","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d151973d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526342667/d151973d8k.htm"},"events":[{"id":26724,"run_id":24299,"accession_number":"0001193125-26-342667","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Jazz Pharmaceuticals entered into an Agreement and Plan of Merger on August 10, 2026, to acquire Actio Biosciences, Inc. for an upfront transaction value of $820 million plus contingent milestone payments up to $500 million. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant M\u0026A transaction that would materially affect investor assessment of the registrant.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27945,"accession_number":"0001193125-26-342667","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Jazz Pharmaceuticals entered into an Agreement and Plan of Merger on August 10, 2026, to acquire Actio Biosciences, Inc. for an upfront transaction value of $820 million plus contingent milestone payments up to $500 million. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant M\u0026A transaction that would materially affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:07:04.760060+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27945,"accession_number":"0001193125-26-342667","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Jazz Pharmaceuticals entered into an Agreement and Plan of Merger on August 10, 2026, to acquire Actio Biosciences, Inc. for an upfront transaction value of $820 million plus contingent milestone payments up to $500 million. This is a material acquisition disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a significant M\u0026A transaction that would materially affect investor assessment of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-11T00:07:04.760060+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-10"}]}